---
layout: post
title: "Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications; Draft Guidance for Industry, Institutional Review Boards, and Clinical Investigators; Availability"
date: 2026-02-05 19:09:19 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-09038
original_published: 2024-04-26 00:00:00 +0000
significance: 8.00
---

# Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications; Draft Guidance for Industry, Institutional Review Boards, and Clinical Investigators; Availability

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** April 26, 2024 00:00 UTC
**Document Number:** 2024-09038

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, institutional review boards (IRBs), and clinical investigators entitled "Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications." This draft guidance is one in a series of guidances that provide recommendations regarding eligibility criteria for clinical trials of investigational drugs regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation Research (CBER) for the treatment of cancer. Specifically, this draft guidance includes recommendations regarding the appropriate use of washout periods and concomitant medication exclusions.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/04/26/2024-09038/cancer-clinical-trial-eligibility-criteria-washout-periods-and-concomitant-medications-draft)
- API: https://www.federalregister.gov/api/v1/documents/2024-09038

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
